Quantum electrochemical sensors for efficient PDAC inhibitor screening
Qnity Bio's quantum electrochemical sensors offer a cost-effective, compound-agnostic solution for screening small molecules and peptides targeting PDAC pathways. Our technology enables precise binding affinity and biochemical metrics, expediting drug discovery.
Overview
Qnity Bio introduces quantum electrochemical sensors designed to revolutionize the screening of small molecules and peptides, particularly for pancreatic ductal adenocarcinoma (PDAC) pathways. This innovative solution provides a streamlined approach to drug discovery, offering a cost-effective and compound-agnostic method for obtaining critical biophysical and biochemical metrics such as binding affinity, IC50, EC50, and ADMET. By enabling the use of attomolar concentrations of test compounds, these sensors significantly reduce consumable costs and enhance binding specificity, eliminating the need for chemical characterization.
Technical specifications
Key features:
- Compound-agnostic technology: Validated for proteins, peptides, and small molecules.
- Cost-effective: Operates at attomolar concentrations, reducing consumable costs.
- High specificity: Immobilization on sensor surfaces directs binding and blocks non-specific sites.
- Comprehensive metrics: Capable of providing binding affinity, IC50, EC50, ADMET, and other enzymatic assay data.
- Efficient process: Integrates multiple screening metrics into a single platform, minimizing equipment needs.
Technology readiness level
Currently, our technology is at TRL 4, indicating that it has been validated in a laboratory setting. We are progressing through a structured validation process, including panel and library development, assay creation, and comprehensive screening stages, to advance its readiness for broader applications.
About Qnity Bio
Qnity Bio is a deep-tech company that has developed a quantum-electrochemical platform designed to transform molecular screening and drug discovery. Their technology utilizes custom-built chips equipped with nanogold-silicon electrodes and quantum sensing capabilities to detect molecular binding events and chemical reactions at attomolar concentrations. By providing label-free, real-time analysis, the system offers significantly higher sensitivity compared to traditional methods such as SPR and ELISA, enabling researchers to screen molecule sizes ranging from small organics to complex biologics with greater precision and scalability.
This technology addresses critical bottlenecks in pharmaceutical research, where traditional screening is often slow, expensive, and limited by low resolution. By delivering accessible, high-throughput molecular data, Qnity aims to accelerate preclinical validation and de-risk drug development decisions for innovators in the pharmaceutical and biotechnology industries. The company has engaged in strategic pilots with industry partners and is supported by specialized scientific expertise and global research initiatives, positioning its platform to expand into broader applications across proteomics, genomics, and metabolomics.
delivered to your inbox.